Research Proposal

Merck was a pharmaceutical manufacturer while Medco Cost Containment Services was a pharmacy benefit manager (PBM). On November 18th, 1993, Merck purchased Medco for $6.6 billion. Immediately after this merger, Medco operated as a subsidiary of Merck. This acquisition of Medco by Merck is a clear example of Merck expanding its organizational boundaries while adding value to Mercks operations at the same time. The advantages of Merck & Medco combining together are that it would result in the control of the entire drug manufacturing and selling process. Merck can manufacture drugs specific to each patients need with collected information being used to research and develop new drugs for sale.

Those target markets who rely on Johnson & Johnson health and medical needs are mostly patients, doctors, nurses and civilians. Therefore, the company need to sustain their products and services over all these years to ensure that lower income people and underprivileged patients are able to access on their medicines. This however requires the company to balance patient’s access and competitive dynamics in line with their need as the company need to have enough resources to keep on being innovating, creating new and better medicines and at the same time making sure there will be a fair return to the shareholder as well. Johnson & Johnson also work closely with the governments, physicians, non-government organizations and the international donors all around the world to provide its products within an affordable prices to its

“The developed world deprives children of a basic and inalienable right: unstructured outdoor play. Children today have substantially less access to nature, less free range, and less time for independent play than previous generations had.” This quote is from the research based paper titled, “Where the Wild Things Should Be: Healing Nature Deficit Disorder through the Schoolyard." This article touches many aspects of how children now a days need more exposure to nature like it was on the older days. Currently, there are many playgrounds around the United States and even more the world. This article is trying to bring awareness to the problem of if playgrounds do not have enough nature or is too safe then it is

Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well

My top ten research topics that I find interesting to pursue are the following: (1) approach for extra ( increase in minimum wage) income and advertising, (2) concussions in football, (3) should transportation security (TSA) regulations be changed ?, (4) should regulations regarding the use of cellular phones while driving be standardized ?, (5) should driving under the influence (DUI) laws be changed ?, (6) concealed guns be permitted in stores, (7) computer forensics, (8) financial crimes, such as embezzlement, (9) cyber terrorism, (10) cyber criminology, internet child pornography.

1. On balance, do you think Merck is an ethical and socially responsible company? Why or why not? How about Pfizer?

The Medco acquisition was the consequence of a study initiated in 1992 by Merck to examine the role of pharmaceuticals in the larger context of health care. Merck realized that drug companies had to view themselves as health care solution providers rather than as suppliers of medicines. Merck also realized that drugs were becoming commodities due to generics and HMOs. Merck felt that the acquisition of a PBM would provide access to key players in the health care industry such as physicians, employers, pharmacists and patients. The huge amounts of drug

1. Blake, Hannah. “A history of Merck & Co”. Pharmaphorum. May 30, 2013. Retrieved from http://www.pharmaphorum.com/articles/a-history-of-merck-co

Now that the product claim, healthcare market, and product has been established, it’s important to interpret the steps found previously to the vaccination patch. In doing so, this will establish the roles of each management team as well as vision of the product. This clear and concise strategy will be utilized to help receive sponsors. It includes the exact outline of the path needed in order for the product to be successful. This includes the company executives, investors, scientists, the project manager, and medical professionals as it requires various aspects of the company in order to produce the vaccination patch. More specifically, the vaccination patch will include the requirements of developing the vaccination patch in not only the United States but also in other countries as well. This further enable options such as distribution channels focused on meeting needs of those in underdeveloped countries. This is a 3-4 month time frame is as every detail must be accounted for in precision.

When you developed your research proposal, what did you think Happy Dogs’ research need was?

In application, people might view Merck’s duties in different ways. For example, one might argue that as a company Merck only has responsibilities to release effective and safe medications and to make a profit to stay in business. On the other hand, it could be argued that as a pharmaceutical company Merck has special obligations to follow leads (like ivermectin) because they may greatly benefit human beings or save lives despite being unprofitable.

Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has

Merck was established in 1891 to improve human and animal health through the development of innovative products. Merck currently has two reportable segments, the Pharmaceutical Segment and the Vaccines and Infectious Diseases Segment. Merck sells products through several channels including wholesalers, retailers, hospitals, clinics, government and managed health services providers. In the 1980’s the Merck was very successful in producing 10 major new drugs and had a very healthy pipeline. In later years, Merck has entered into joint ventures with many other pharmaceutical companies in order to expand its pipeline. In the last several years Merck has

[Note: This sample proposal is based on a composite of past proposals, simulated information and references, and material I’ve included for illustration purposes – it is based roughly on a fairly standard research proposal; I say roughly because there is no one set way of creating a quantitative research proposal. Much of its design is based on the nature of the research, your preferences, and your decisions regarding how to describe or portray what it is you plan to accomplish. The material in this document was adopted from a dissertation proposal created by Dr. Ralph Brockett. A biography

In the late 1970s, Merck was falling off a 10-year dry season as far as new items. For about 10 years, the organization had depended on two physician endorsed drugs for a critical rate of its around $2 billion in yearly deals: Indocin, a treatment for rheumatoid joint inflammation, and Aldomet, a treatment for hypertension. Henry W. Gadsden, Merck's CEO from 1965 to 1976, alongside his successor, John J. Horan, were worried that the 17-year patent security on Merck's two major moneymakers would soon terminate, and started putting a tremendous sum in research.